Nausicaa Ventures
Nausicaa Ventures is a venture capital firm based in Louvain-la-Neuve, Belgium, with an additional office in Mechelen. Founded in 2009, it focuses on financing early stage and early growth companies primarily in and around Belgium, specifically within a 300 km radius of Brussels. The firm typically invests between €1 million and €4 million in sectors such as healthcare, information and communications technology, traditional manufacturing, clean technology, and industrial processes. Nausicaa Ventures prefers to partner with companies that already have support from angel investors or family offices. The firm has a holding period averaging five years and aims to exit investments within three to six years. By combining the resources of institutional investors with those of private investors, Nausicaa Ventures seeks to address the equity gap faced by promising early stage companies as they strive for profitable growth.
Ovizio specializes in digital holographic interferometric microscopy, creating advanced 4D microscopic imaging devices and associated software. The company targets scientists and biomanufacturers by offering automated cell culture monitoring and analysis systems that enhance the scaling of cell culture processes. Its technology is primarily aimed at the life sciences sector, specifically in bioprocessing and research and development. By utilizing digital holographic microscopy, Ovizio provides innovative solutions that support the growth and efficiency of scientific operations.
Bone Therapeutics SA is a biotechnology company based in Gosselies, Belgium, that specializes in developing cell therapy products aimed at treating orthopedic conditions and bone diseases. The company's lead product, ALLOB, is an allogeneic cell therapy currently undergoing Phase II clinical trials for addressing delayed-union fractures and spinal fusion procedures. In addition to ALLOB, Bone Therapeutics is also advancing its PREOB product and conducting preclinical research on next-generation candidates, including combined cell-matrix products for large bone defects and applications in maxillofacial surgery. The company collaborates with partners such as Cerhum, 3D-Side, mSKIL, and IREC to innovate in personalized, tissue-engineered bone implants. With a focus on advancing treatment options through its expertise in bone and joint physiology and cell transplantation, Bone Therapeutics aims to provide effective solutions for patients with challenging bone conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.